Diabetic Retinopathy Market
- The total Diabetic Retinopathy prevalent cases in the 7MM were 12,585,769 in 2021.
- In 2021, the Diabetic Retinopathy market size in the seven major markets was found to be USD 126,851 million, which is expected to grow by 2032.
- Some of the key companies in the Diabetic Retinopathy market include Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, and others.
Request for sample pages to learn more about the market CAGR and key trends Diabetic Retinopathy Market
DelveInsight’s ‘Diabetic Retinopathy–Market Insights, Epidemiology, and Market Forecast—2032’ report deliver an in-depth understanding of the Diabetic retinopathy, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Diabetic retinopathy market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Diabetic retinopathy symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Diabetic retinopathy symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2019–2032
Diabetic Retinopathy Disease Understanding and Treatment Algorithm
Diabetic Retinopathy Overview
Diabetic retinopathy (DR) is a common and specific microvascular complication of diabetes and remains the leading cause of preventable blindness in working-aged people. It is identified in a third of people with diabetes and is associated with increased risk of life-threatening systemic vascular complications, including stroke, coronary heart disease, and heart failure. In the USA, an estimated 40% (8% for vision-threatening retinopathy) of people with type 2 diabetes and 86% (42%) with type 1 diabetes have diabetic retinopathy.
Several large studies have shown that the onset of DR is generally not observed within the first 5 years after the diagnosis of type 1 diabetes. In contrast, the commencement of type 2 diabetes is often more insidious, and as such, the retinal disease may be present at the time of diagnosis. Therefore, screening for DR is recommended at the time of diagnosis in type 2 diabetics. Chronic hyperglycemia and its cardinal parameter, HbA1c, have been directly linked to DR. In this regard, the ophthalmologist plays an essential role by screening patients with diabetes mellitus, motivating them to control their glucose levels, and explaining the sequelae of DR progression, including visual impairment.
Diabetic retinopathy (DR) is essentially, but not exclusively, a micro vascular disease. Individual DR features help the clinician to evaluate the risk of imminent visual impairment ( e.g., subfoveal macular edema, new vessels) as well as that of significant future risk (e.g., extra/juxtafoveal macular edema, surrogate markers of capillary non-perfusion or leakage), thus assisting in developing a management plan for an individual patient. The classification of diabetic retinopathy has a dichotomous approach – the presence or absence of new vessels and the presence or absence of subfoveal macular edema. However, despite its importance, the pathogenesis of many retinopathy features is not fully understood.
There are several important risk factors for diabetic retinopathy. Ethnic origin differences in the prevalence of diabetic retinopathy have been a focal point of interest in research. Findings from population-based studies suggest that the prevalence and severity of diabetic retinopathy are higher in African Americans, Hispanics, and South Asians than in white people, and are not fully accounted for by differences in the distribution of retinopathy risk factors.
Diabetic retinopathy falls into two main classes: nonproliferative and proliferative. The word “proliferative” refers to whether or not there is neovascularization (abnormal blood vessel growth) in the retina. Early disease without neovascularization is called nonproliferative diabetic retinopathy (NPDR). As the disease progresses, it may evolve into proliferative diabetic retinopathy (PDR), which is defined by the presence of neovascularization and has a greater potential for serious visual consequences.
The most common cause of vision loss in patients with DR is diabetic macular edema (DME). DME is characterized by swelling or thickening of the macula due to sub- and intra-retinal accumulation of fluid in the macula triggered by the breakdown of the blood-retinal barrier (BRB).
In some cases of diabetic maculopathy, injections of a medicine called anti-VEGF may be given directly into the eyes to prevent new blood vessels forming at the back of the eyes. The main medicines used are called ranibizumab (Lucentis) and aflibercept (Eylea).
Diabetic Retinopathy Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Diabetic retinopathy market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Diabetic retinopathy market report gives a thorough understanding of Diabetic retinopathy symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Diabetic retinopathy treatment algorithms and treatment guidelines in the US, Europe, and Japan.
Diabetic Retinopathy Epidemiology
The epidemiology division’s Diabetic retinopathy symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Diabetic retinopathy epidemiology segmented as the Total Prevalent cases of Diabetic retinopathy, Gender-specific of Diabetic retinopathy, Severity-specific cases of Diabetic Retinopathy, Age-specific cases of Diabetic Retinopathy. The report includes the prevalent Diabetic retinopathy scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Diabetic Retinopathy Epidemiology
The epidemiology segment also provides the Diabetic retinopathy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total 7MM prevalent cases of Diabetic retinopathy were 12,585,769 in 2021.
Diabetic Retinopathy Drug Chapters
The drug chapter segment of the Diabetic retinopathy report encloses the detailed analysis of Diabetic retinopathy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Diabetic retinopathy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Products detail in the report…
Diabetic Retinopathy Emerging Drugs
OPT-302: Opthea Limited
OPT-302 is a first-in-class VEGF-C/D inhibitor. It is a soluble fusion protein comprising immunoglobulin-like domains 1 to 3 of the extracellular domain of vascular endothelial growth factor receptor 3 (VEGFR-3) fused to the Fc fragment of human immunoglobulin G1 (IgG1) (Opthea, 2019).
OPT-302 is a soluble form of VEGFR-3 which binds (“traps”) human VEGF-C and VEGF-D with high affinity, neutralizing their activity by preventing them from binding to both VEGFR-2 and VEGFR-3 (Opthea, 2019).
RGX 314: Regenxbio
It is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions. RGX-314 consists of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF). RGX-314 is believed to inhibit the VEGF pathway by which new, leaky blood vessels grow and contribute to the fluid accumulation in the retina.
Runcaciguat (BAY 1101042): Bayer
The sGC enzyme, via the formation of cyclic guanosine monophoshphate, is a key regulator of body and tissue homeostasis. sGC activators with their unique mode of action are activating the oxidized and heme-free and therefore NO-unresponsive form of sGC, which is formed under oxidative stress. Runcaciguat is currently investigated in clinical phase 2 studies for the treatment of patients with chronic kidney disease and nonproliferative diabetic retinopathy (Hahn et al., 2021).
Products detail in the report…
Diabetic Retinopathy Market Outlook
The Diabetic retinopathy market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Diabetic retinopathy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Diabetic retinopathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Diabetic retinopathy market in 7MM is expected to change in the study period 2019–2032.
This section includes a glimpse of the Diabetic retinopathy market in 7MM. The market size of Diabetic retinopathy in the seven major markets was found to be USD 126,851 million in 2021.
The United States Market Outlook
This section provides a total of Diabetic retinopathy market size and market size by therapies in the United States.
The United States accounts for the highest Diabetic retinopathy market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
EU-5 Countries: Market Outlook
The total Diabetic retinopathy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Diabetic retinopathy market size and market size by therapies in Japan are also mentioned.
Diabetic Retinopathy Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019–2032. The analysis covers Diabetic retinopathy market uptake by drugs, patient uptake by therapies, and drug sales.
This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.
Diabetic Retinopathy Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Diabetic retinopathy key players involved in developing targeted therapeutics.
Major players Brolucizumab (Novartis Pharmaceuticals), LKA651 (Novartis Pharmaceuticals), Risuteganib (Allegro Ophthalmics LLC), ADVM-022 (Adverum Biotechnologies Inc.) etc being assessed as potential therapies to be available in the market in the coming future.
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Diabetic retinopathy emerging therapies.
To keep up with current market trends, we take KOLs and SME’s opinion working Diabetic retinopathy domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapies treatment patterns or Diabetic retinopathy market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.
Competitive Intelligence Analysis
We perform a Competitive and Market Intelligence analysis of the Diabetic retinopathy Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
2019 to 2032
2022 to 2032
|USD 126,851 million in 2021|
|Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd., and others|
Scope of the Report
- The report covers the descriptive overview of Diabetic retinopathy explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
- Comprehensive insight has been provided into the Diabetic retinopathy epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Diabetic retinopathy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Diabetic retinopathy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies by understanding trends shaping and driving the global Diabetic retinopathy market
- In the coming years, Diabetic retinopathy market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic retinopathy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Diabetic retinopathy. The launch of emerging therapies will significantly impact the Diabetic retinopathy market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Diabetic retinopathy
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Diabetic Retinopathy Report Insights
- Patient Population
- Therapeutic Approaches
- Diabetic retinopathy Pipeline Analysis
- Diabetic retinopathy Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Diabetic Retinopathy Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Diabetic retinopathy Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Diabetic Retinopathy Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- What was the Diabetic retinopathy Market share (%) distribution in 2019, and how would it look in 2032?
- What would be the Diabetic retinopathy total market Size as well as market Size by therapies across the 7MM during the forecast period (2019–2032)?
- What are the market’s key findings across 7MM, and which country will have the largest Diabetic retinopathy market Size during the forecast period (2019–2032)?
- At what CAGR, the Diabetic retinopathy market is expected to grow by 7MM during the forecast period (2019–2032)?
- What would be the Diabetic retinopathy market outlook across the 7MM during the forecast period (2019–2032)?
- What would be the Diabetic retinopathy market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
- What are the disease risk, burden, and unmet needs of Diabetic retinopathy?
- What is the historical Diabetic retinopathy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Diabetic retinopathy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What will be the growth opportunities in the 7MM concerning the patient population about Diabetic retinopathy?
- Out of all 7MM countries, which country would have the highest prevalent Diabetic retinopathy population during the forecast period (2019–2032)?
- At what CAGR is the population expected to grow by 7MM during the forecast period (2019–2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of Diabetic retinopathy?
- What are the current treatment guidelines for treating Diabetic retinopathy in the USA, Europe, and Japan?
- What are the Diabetic retinopathy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of Diabetic retinopathy?
- How many therapies are developed by each company for the treatment of Diabetic retinopathy?
- How many emerging therapies are in the mid-stage and late development stages to treat Diabetic retinopathy?
- What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic retinopathy therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diabetic retinopathy and their status?
- What are the key designations that have been granted for the emerging therapies for Diabetic retinopathy?
- What are the global historical and forecasted markets of Diabetic retinopathy?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Diabetic retinopathy market
- To understand the future market competition in the Diabetic retinopathy market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Diabetic retinopathy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Diabetic retinopathy market
- To understand the future market competition in the Diabetic retinopathy market
Frequently Asked Questions
1. Key Insights
2. Report Introduction
3. Diabetic Retinopathy Market Overview at a Glance
3.1. Market Share (%) Distribution of Diabetic Retinopathy in 2019
3.2. Market Share (%) Distribution of Diabetic Retinopathy in 2032
4. Executive Summary of Diabetic Retinopathy
5. Disease Background and Overview
5.2. Diabetes Mellitus
5.2.1. Type 1 Diabetes Mellitus
5.2.2. Type 2 Diabetes Mellitus
5.4. Clinical Presentation
5.6. Risk Factors
6. Management and Treatment
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Total prevalent cases of Diabetic Retinopathy in the 7MM
7.3. Assumptions and Rationale
7.4. The United States
7.4.1. Total prevalent cases of Diabetic Retinopathy in the United States
7.4.2. Gender-specific cases of Diabetic Retinopathy in the United States
7.4.3. Severity-specific cases of Diabetic Retinopathy in the United States
7.4.4. Age-specific cases of Diabetic Retinopathy in the United States
7.5. The EU5
7.5.1. Total prevalent cases of Diabetic Retinopathy in the EU5
7.5.2. Gender-specific cases of Diabetic Retinopathy in the EU5
7.5.3. Severity-specific cases of Diabetic Retinopathy in the EU5
7.5.4. Age-specific cases of Diabetic Retinopathy in the EU5
7.6.1. Total prevalent cases of Diabetic Retinopathy in Japan
7.6.2. Gender-specific cases of Diabetic Retinopathy in Japan
7.6.3. Severity-specific cases of Diabetic Retinopathy in Japan
7.6.4. Age-specific cases of Diabetic Retinopathy in Japan
8. Patient Journey 1
9. Patient Journey 2
10. Marketed Drugs
10.1. Lucentis (Ranibizumab): Genentech, Inc.
10.1.1. Drug Description
10.1.2. Other Development Information
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
10.1.6. Product Profile
10.2. Eylea (Aflibercept): Regeneron Pharmaceuticals
10.2.1. Drug Description
10.2.2. Other Development Information
10.2.3. Clinical Development
10.2.4. Clinical Trials Information
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.3. Vabysmo™ (Faricimab): Genentech, Inc. / Roche
10.3.1. Drug Description
10.3.2. Other Development Information
10.3.3. Clinical Development
10.3.4. Clinical Trials Information
10.3.5. Safety and Efficacy
10.3.6. Product Profile
11. Emerging Drugs
11.1. OPT-302: Opthea Limited
11.1.1. Drug Description
11.1.2. Clinical Development
11.1.3. Clinical Trials Information
11.1.4. Product Profile
11.2. RGX 314: Regenxbio
11.2.1. Drug Description
11.2.2. Clinical Development
11.2.3. Clinical Trials Information
11.2.4. Product Profile
11.3. KSI-301: Kodiak Sciences Inc.
11.3.1. Drug Descriptions
11.1.2. Other Developmental Activities
11.3.3. Clinical Development
11.3.4. Clinical Trials Information
11.3.5. Safety and Efficacy
11.3.6. Product Profile
11.4. APX3330: Ocuphire Pharma/Eisai Co Ltd/Apexian Pharmaceuticals
11.4.1. Drug Descriptions
11.1.2. Other Developmental Activities
11.4.2. Clinical Development
11.4.3. Clinical Trials Information
11.4.4. Safety and Efficacy
11.4.5. Product Profile
11.5. OCS-01: Oculis
11.5.1. Drug Descriptions
11.5.2. Clinical Development
11.5.3. Clinical Trials Information
11.5.4. Safety and Efficacy
11.5.5. Product Profile
11.6. Runcaciguat (BAY 1101042): Bayer
11.6.1. Drug Descriptions
11.6.2. Clinical Development
11.6.3. Clinical Trials Information
11.6.4. Product Profile
11.7. Brolucizumab: Novartis Pharmaceuticals
11.7.1. Drug Descriptions
11.7.2. Other Developmental Activities
11.7.3. Clinical Development
11.7.4. Clinical Trials Information
11.7.5. Product Profile
11.8. LKA651: Novartis Pharmaceuticals
11.8.1. Drug Descriptions
11.8.2. Clinical Development
11.8.3. Clinical Trials Information
11.8.4. Product Profile
11.9. Risuteganib: Allegro Ophthalmics, LLC
11.9.1. Drug Descriptions
11.9.2. Clinical Development
11.9.3. Clinical Trials Information
11.9.4. Safety and Efficacy
11.9.5. Product Profile
11.10. ADVM-022: Adverum Biotechnologies, Inc.
11.10.1. Drug Descriptions
11.10.2. Clinical Development
11.10.3. Clinical Trials Information
11.10.4. Safety and Efficacy
11.10.5. Product Profile
11.11. GB-102: Graybug Vision
11.11.1. Drug Descriptions
11.11.2. Clinical Development
11.11.3. Clinical Trials Information
11.11.4. Product Profile
11.12. Emixustat Hydrochloride: Kubota Vision Inc.
11.12.1. Drug Descriptions
11.12.2. Other Developmental Activities
11.12.3. Clinical Development
11.12.4. Clinical Trials Information
11.12.5. Product Profile
11.13. KVD001: KalVista Pharmaceuticals Ltd.
11.13.1. Drug Descriptions
11.13.2. Other Developmental Activities
11.13.3. Clinical Development
11.13.4. Clinical Trials Information
11.13.5. Product Profile
11.14. RG7774: Roche
11.14.1. Drug Descriptions
11.14.2. Clinical Development
11.14.3. Clinical Trials Information
11.14.4. Product Profile
12. Other Therapy
13. Diabetic Retinopathy: Seven Major Market Analysis
13.1. Key Findings
13.2. Market Size of Diabetic Retinopathy in the 7MM Countries
13.3. Market Size of Diabetic Retinopathy by Therapies in the 7MM Countries
13.4. 7MM Market Outlook
13.5. The United States Market Size
13.5.1. Total Market Size of Diabetic Retinopathy in the United States
13.5.2. Market Size by Therapies of Diabetic Retinopathy in the United States
13.6. The EU5 Market Size
13.6.1. Total Market size of Diabetic Retinopathy in the EU5
13.6.2. Market Size by Therapies of Diabetic Retinopathy in the EU5
13.7.1. Total Market Size of Diabetic Retinopathy in Japan
13.7.2. Market Size of Diabetic Retinopathy by Therapies in Japan
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17.2. Report Methodology
18. DelveInsight Capabilities
20. About DelveInsight
List of Table
Table 1: Summary of Diabetic Retinopathy, Market, Epidemiology, and Key Events (2019–2032)
Table 2: Risk Factors of Diabetic Retinopathy
Table 3: Genetic polymorphisms and diabetic retinopathy
Table 4: Total Prevalent Cases of Diabetic Retinopathy in the 7MM (2019–2032) (in ‘000’s)
Table 5: Total prevalent cases of Diabetic Retinopathy in the US (2019–2032) (in ‘000’s)
Table 6: Gender-specific Prevalence of Diabetic Retinopathy in the United States (2019–2032) (in ‘000’s)
Table 7: Severity-specific cases of Diabetic Retinopathy in the United States (2019–2032)
Table 8: Age-specific cases of Diabetic Retinopathy in the United States (2019–2032) (in ‘000’s)
Table 9: Total daignosed cases of Diabetic Retinopathy in the EU5 (2019–2032)
Table 10: Gender-specific cases of Diabetic Retinopathy in the EU5 (2019–2032)
Table 11: Severity-specific cases of Diabetic Retinopathy in the EU5 (2019–2032)
Table 12: Age-specific cases of Diabetic Retinopathy in the United States (2019–2032)
Table 13: Total prevalent cases of Diabetic Retinopathy in Japan (2019–2032)
Table 14: Gender-specific cases of Diabetic Retinopathy in Japan (2019–2032)
Table 15: Severity-specific cases of Diabetic Retinopathy in Japan (2019–2032)
Table 16: Age-specific cases of Diabetic Retinopathy in Japan (2019–2032)
Table 17: Lucentis (Ranibizumab), Clinical Trial Description, 2022
Table 18: Eylea (Aflibercept), Clinical Trial Description, 2022
Table 19: Vabysmo (Faricimab), Clinical Trial Description, 2022
Table 20: OPT-302, Clinical Trial Description, 2022
Table 21: RGX 314, Clinical Trial Description, 2022
List of Figures
Figure 1: Polyol pathway
Figure 2: Pathways involved in Diabetic Retinopathy
Figure 3: Risk factors for Diabetic Retinopathy
Figure 4: Treatment guidelines by the American Academy of Ophthalmology
Figure 5: Total Prevalent cases of Diabetic Retinopathy in the 7MM (2019–2032)
Figure 6: Total prevalent cases of Diabetic Retinopathy in the US (2019–2032)
Figure 7: Gender-specific Prevalence of Diabetic Retinopathy in the United States (2019–2032)
Figure 8: Severity-specific cases of Diabetic Retinopathy in the United States (2019–2032)
Figure 9: Age-specific cases of Diabetic Retinopathy in the United States (2019–2032)
Figure 10: Total prevalent cases of Diabetic Retinopathy in the EU5 (2019–2032)
Figure 11: Gender-specific cases of Diabetic Retinopathy in the EU5 (2019–2032)
Figure 12: Severity-specific cases of Diabetic Retinopathy in the EU5 (2019–2032)
Figure 13: Age-specific cases of Diabetic Retinopathy in the EU5 (2019–2032)
Figure 14: Total prevalent cases of Diabetic Retinopathy in Japan (2019–2032)
Figure 15: Gender-specific cases of Diabetic Retinopathy in Japan (2019–2032)
Figure 16: Severity-specific cases of Diabetic Retinopathy in Japan (2019–2032)
Figure 17: Age-specific cases of Diabetic Retinopathy in Japan (2019–2032)
Figure 18: Market size of Diabetic Retinopathy in the 7MM (2019–2032)
Figure 19: Market size of Diabetic Retinopathy by therapies in the 7MM (2019–2032)
Figure 20: Market size of Diabetic Retinopathy in the United States (2019–2032)
Figure 21: Market size of Diabetic Retinopathy by therapies in the US (2019–2032)
Figure 22: Market size of Diabetic Retinopathy in the EU5 (2019–2032)
Figure 23: Market size of Diabetic Retinopathy by therapies in the EU5 (2019–2032)
Figure 24: Market Size of Diabetic Retinopathy in Japan (2019–2032)
Figure 25: Market size of Diabetic Retinopathy by therapies in Japan (2019–2032)
Kodiak Sciences Inc
Eisai Co Ltd
Allegro Ophthalmics, LLC
Adverum Biotechnologies, Inc.
Kubota Vision Inc.
KalVista Pharmaceuticals Ltd.